Henry James International Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Henry James International Management’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-43,070	Closed	-$162K	–	121
2021 Q4	$162K	Hold	43,070	–	–	0.05%	142
2021 Q3	$223K	Hold	43,070	–	–	0.07%	142
2021 Q2	$183K	Sell	43,070 -43,000	-50%	-$209K	0.05%	155
2021 Q1	$457K	Buy	+86,070	New	+$493K	0.14%	123
2019 Q1	–	Sell	-25,027	Closed	-$144K	–	144
2018 Q4	$144K	Buy	+25,027	New	+$185K	0.09%	136

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Henry James International Management's ADAP Position: Q1 2022 in Review

Henry James International Management sold out of Adaptimmune Therapeutics (ADAP) in Q1 2022, closing a stake of 43,070 shares — an estimated $162K sold.

Henry James International Management first reported a position in ADAP in Q4 2018 and held it in 5 quarters. The position peaked at $457K in Q1 2021. 80 funds tracked by Wall St. Rank hold ADAP as of Q1 2022.

Henry James International Management reported no remaining Adaptimmune Therapeutics position as of Q1 2022 after selling out during the quarter.
Henry James International Management sold 43,070 Adaptimmune Therapeutics shares in Q1 2022, an estimated $162K.
Henry James International Management first reported a position in Adaptimmune Therapeutics in Q4 2018 and held it in 5 quarters.
Henry James International Management's Adaptimmune Therapeutics position peaked at $457K in Q1 2021.
80 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2022.

Based on Henry James International Management's 13F filing for Q1 2022, filed 21 Apr 2022.